Future Science Group (FSG) has announced the publication of the first issue of its new open access journal, Future Drug Discovery.
Future Drug Discovery is a peer-reviewed, open access journal for drug discovery and development research. Published quarterly, it provides a forum for discussion of the state of the drug discovery field, alongside research, review and methodology articles.
The journal is led by an international, expert advisory board including Jayanth Panyam (University of Minnesota, MN, USA), Steve Rees (Astrazeneca, Cambridge, UK) and Neil Jones (Cancer Research UK, London, UK), among other leading names in the field.
The first issue includes opinion pieces discussing the state of publishing in drug discovery, the importance of chromatographic separation in early phase discovery, the benefits of working in a science incubator and a perspective on working as an independent consultant. Additionally, the issue also features an interview discussing how the future of antibiotics lies in combination treatments; commentaries detailing an open science rare diseases initiative and self-assembling technology for drug delivery; and research articles covering nanoparticles, nootropics and Rule of 5.
The full first issue is available open access and can be read here: https://www.future-science.com/toc/fdd/1/1.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
